Impact of the SGLT2-inhibitor Empagliflozin on inflammatory biomarkers in acute myocardial infarction-a post-hoc analysis of the EMMY trial

被引：0
|
作者：
Benedikt, M. [1 ]
Kolesnik, E. [1 ]
Wallner, M. [1 ]
Zirlik, A. [1 ]
Sourij, H. [2 ]
Tripolt, N. [2 ]
Aziz, F. [2 ]
Vonbank, A. [3 ]
Purkarthofer, D. [4 ]
Wester, S. [5 ]
Kopp, K. [6 ]
Nahler, A. [7 ]
von Lewinski, D. [1 ]
机构：
[1] Med Univ Graz, Kardiol, Graz, Austria
[2] Med Univ Graz, Endokrinol, Graz, Austria
[3] VIVIT LKH Feldkirch, Feldkirch, Feldkirch, Austria
[4] LKH II, Kardiol, Graz, Austria
[5] LKH Klagenfurt, Kardiol, Klagenfurt, Austria
[6] Paracelsus Univ Salzburg, Salzburg, Austria
[7] Kepleruniv Linz, Kardiol, Linz, Austria
来源：
WIENER KLINISCHE WOCHENSCHRIFT | 2023年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1-3
引用
收藏
页码：S359 / S360
页数：2
相关论文
共 50 条
  • [1] Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial
    Martin Benedikt
    Harald Mangge
    Faisal Aziz
    Pero Curcic
    Sabine Pailer
    Markus Herrmann
    Ewald Kolesnik
    Norbert J. Tripolt
    Peter N. Pferschy
    Markus Wallner
    Andreas Zirlik
    Harald Sourij
    Dirk von Lewinski
    Cardiovascular Diabetology, 22
  • [2] Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial
    Benedikt, Martin
    Mangge, Harald
    Aziz, Faisal
    Curcic, Pero
    Pailer, Sabine
    Herrmann, Markus
    Kolesnik, Ewald
    Tripolt, Norbert J.
    Pferschy, Peter N.
    Wallner, Markus
    Zirlik, Andreas
    Sourij, Harald
    von Lewinski, Dirk
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [3] Impact of the SGLT2-inhibitor Empagliflozin on inflammatory biomarkers in acute coronary syndrome-a post-hoc analysis of the EMMY trial
    Curcic, P.
    Herrmann, M.
    Pailer, S.
    Mangge, H.
    Benedikt, M.
    von Lewinski, D.
    Aziz, F.
    Kolesnik, E.
    Tripolt, J. N.
    Pferschy, P.
    Wallner, M.
    Zirlik, A.
    Sourij, H.
    WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 : S361 - S361
  • [4] Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post-hoc analysis of the EMMY trial
    Sourij, Caren
    Oulhaj, Abderrahim
    Aziz, Faisal
    Tripolt, Norbert J.
    Aberer, Felix
    Pferschy, Peter N.
    Postula, Marek
    Drexel, H.
    Benedikt, Martin
    Kolesnik, Ewald
    Pieber, Thomas R.
    Bugger, Heiko
    von Lewinski, Dirk
    Sourij, Harald
    DIABETES OBESITY & METABOLISM, 2024, 26 (05): : 1971 - 1975
  • [5] Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial
    Schwegel, Nora
    Strohhofer, Christoph
    Kolesnik, Ewald
    Oltean, Sabrina
    Huettmair, Alexander
    Pipp, Christian
    Benedikt, Martin
    Verheyen, Nicolas
    Gollmer, Johannes
    Ablasser, Klemens
    Wallner, Markus
    Santner, Viktoria
    Tripolt, Norbert
    Pferschy, Peter
    Zechner, Peter
    Alber, Hannes
    Siller-Matula, Jolanta M.
    Kopp, Kristen
    Zirlik, Andreas
    Aziz, Faisal
    Sourij, Harald
    von Lewinski, Dirk
    CLINICAL RESEARCH IN CARDIOLOGY, 2024,
  • [6] The SGLT2-inhibitor Empagliflozin improves Parameters of Diastolic Function after Myocardial Infarction measured by Echocardiography-a Single Center Sub Analysis of the EMMY-Trial
    Strohhofer, C.
    Oltean, S.
    Huettmair, A.
    Pipp, C.
    Benedikt, M.
    Wallner, M.
    Verheyen, N.
    Gollmer, J.
    Ablasser, K.
    Hanfstingl-Sinz, D.
    Andorfer, J.
    Pachinger-Poessl, S.
    Brunner, M.
    Rogozarski, J.
    Kolesnik, E.
    WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 : S343 - S345
  • [7] Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial
    Tripolt, Norbert J.
    Kolesnik, Ewald
    Pferschy, Peter N.
    Verheyen, Nicolas
    Ablasser, Klemens
    Sailer, Sandra
    Alber, Hannes
    Berger, Rudolf
    Kaulfersch, Carl
    Leitner, Katharina
    Lichtenauer, Michael
    Mader, Arthur
    Moertl, Deddo
    Oulhaj, Abderrahim
    Reiter, Christian
    Rieder, Thomas
    Saely, Christoph H.
    Siller-Matula, Jolanta
    Weidinger, Franz
    Zechner, Peter M.
    von Lewinski, Dirk
    Sourij, Harald
    AMERICAN HEART JOURNAL, 2020, 221 : 39 - 47
  • [8] Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial
    Sourij, Caren
    Aziz, Faisal
    Tripolt, Norbert J.
    Siller-Matula, Jolanta
    Pferschy, Peter N.
    Kolesnik, Ewald
    Wallner, Markus
    Eyileten, Ceren
    Postula, Marek
    Oulhaj, Abderrahim
    Sourij, Harald
    von Lewinski, Dirk
    HELLENIC JOURNAL OF CARDIOLOGY, 2024, 75 : 3 - 8
  • [9] Effects of empagliflozin in women and men with acute myocardial infarction-an analysis from the EMMY trial
    Wallner, M.
    Sourij, C.
    Aziz, F.
    Tripolt, N.
    Siller-Matula, J.
    Säly, C.
    Hoppe, U.
    Mayrhofer, G.
    Alber, H.
    Steinwender, C.
    Mortl, D.
    Zechner, P.
    Weidinger, F.
    Postula, M.
    Benedikt, M.
    Kolesnik, E.
    Oulhaj, A.
    Sourij, H.
    von Lewinski, D.
    WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 : S359 - S359
  • [10] Influence of the SGLT2 inhibitor empagliflozin on post myocardial infarction rat hearts
    Damatto, F. C.
    Paschoareli, G. L.
    Rosa, C. M.
    Gomes, M. J.
    Pagan, L. U.
    Damatto, R. L.
    Rodrigues, E. A.
    Pontes, T. H.
    Reyes, D. R. A.
    Cezar, M. D. M.
    Oliveira, L. R. S.
    Zornoff, L. A. M.
    Rego, A. B. G. C.
    Okoshi, M. P.
    Okoshi, K.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1115 - 1115
12345